The KYAT3 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from HeLa cells, with targeted disruption of the KYAT3 gene encoding kynurenine aminotransferase. This loss-of-function model facilitates investigation of the tryptophan-catabolic kynurenine pathway by abolishing the conversion of kynurenine to kynurenic acid. The polyclonal format captures a spectrum of editing outcomes, suitable for population-based metabolic and signaling analyses without clonal bias.
HeLa cells, derived from human cervical adenocarcinoma, are positive for HPV-18 and exhibit aneuploidy, making them a quintessential model for epithelial cancer research. Their extensive use spans decades, with well-annotated genomic and proteomic resources that facilitate phenotypic integration. The rapid doubling time and ease of genetic manipulation, combined with their epithelial nature, make them particularly valuable for studying metabolic pathways in carcinoma contexts, including how kynurenine pathway alterations might influence tumor cell behavior.
KYAT3 is a pyridoxal phosphate-dependent aminotransferase catalyzing kynurenine to kynurenic acid, a neuroactive metabolite that antagonizes NMDA and ??7 nicotinic acetylcholine receptors and activates GPR35. It is regulated by aryl hydrocarbon receptor (AhR), glucocorticoid receptor, NRF2, and cytokines such as IFN?? and TNF??. The reaction competes with kynurenine 3-monooxygenase (KMO) for substrate, affecting metabolic flux toward quinolinic acid and NAD+ biosynthesis. Knockout disrupts kynurenic acid production, leading to kynurenine buildup and altered tryptophan catabolism, with impacts on glutamatergic signaling.
In HeLa cells, which express tryptophan-catabolizing enzymes like indoleamine 2,3-dioxygenase (IDO1) and tryptophan 2,3-dioxygenase (TDO2), KYAT3 loss redirects kynurenine toward alternative branches, potentially increasing quinolinic acid or AhR ligand production. This provides a model to study how kynurenine pathway dynamics affect epithelial cancer cell proliferation, migration, and inflammatory responses. The knockout system enables dissection of kynurenic acid’s autocrine or paracrine roles in tumor biology.
Researchers can utilize these cells in a range of assays, including quantitative LC-MS/MS measurement of kynurenine and kynurenic acid to assess metabolic flux, western blotting and RT-qPCR for confirming knockout and evaluating pathway components, and enzyme activity assays. Functional studies such as intracellular calcium imaging to monitor NMDA receptor responses and cell proliferation assays further extend the model??s utility. Additionally, these polyclonal knockout cells are well-suited for drug screening campaigns targeting IDO1, TDO2, KMO, or KYAT3 itself. For further details or to inquire about this product, please contact Ascent Research.
